Different therapies could take advantage of DDR pathways’ defects to induce additional tumor genetic structural damage, as with radiotherapy, cytotoxic chemotherapies, or targeted DNA repair mechanisms such as PARP inhibitors, to enhance tumors cells’ lethality (3). The gene discussed is PARP1; the disease is neoplasm.